Valuation: OLIPASS Corporation

Market Cap 26.53B 18.77M 16.21M 15.23M 13.85M 26.05M 1.79B 26.48M 178M 69.79M 899M 70.47M 68.94M 2.99B P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 20.34B 14.39M 12.43M 11.68M 10.62M 19.96M 1.38B 20.29M 137M 53.49M 689M 54.01M 52.84M 2.29B EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
34,500
5 years 1,568
Extreme 1568
146,500
10 years 1,568
Extreme 1568
240,666.67
Manager TitleAgeSince
Chief Executive Officer 54 22/05/2025
Corporate Officer/Principal 34 28/11/2024
Comptroller/Controller/Auditor 67 31/03/2025
Director TitleAgeSince
Director/Board Member 54 28/11/2024
Director/Board Member 34 28/11/2024
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-92.37% 9.5M
-1.90%+11.59%+62.29%+102.60% 71.56B
-3.21%-4.32%+31.19%+59.75% 54.43B
-2.68%-6.16%-3.69%+451.70% 27.59B
-1.27%+9.09%+46.56%+4.13% 23.91B
-0.55%-2.00%-18.54%-14.56% 23.14B
+0.10%+1.40%+38.98%-20.04% 18.65B
+3.81%+16.28%+270.78%+488.06% 18.64B
-0.95%+2.46%+24.40%+574.22% 16.01B
+0.05%-6.31%+31.69%+135.52% 12.54B
Average -2.02%-1.92%+48.37%+168.90% 26.65B
Weighted average by Cap. -1.36%+1.72%+49.91%+159.24%

Financials

2021 2022
Net sales 852M 603K 520K 489K 445K 836K 57.62M 850K 5.73M 2.24M 28.85M 2.26M 2.21M 95.89M 2.3B 1.62M 1.4M 1.32M 1.2M 2.25M 155M 2.29M 15.45M 6.04M 77.78M 6.1M 5.97M 258M
Net income -25.13B -17.78M -15.36M -14.43M -13.12M -24.68M -1.7B -25.08M -169M -66.11M -851M -66.76M -65.31M -2.83B -24.17B -17.1M -14.77M -13.88M -12.62M -23.73M -1.63B -24.12M -163M -63.57M -819M -64.19M -62.8M -2.72B
Net Debt -18.29B -12.94M -11.18M -10.5M -9.55M -17.96M -1.24B -18.25M -123M -48.11M -620M -48.58M -47.53M -2.06B -6.2B -4.38M -3.79M -3.56M -3.23M -6.08M -419M -6.18M -41.68M -16.3M -210M -16.45M -16.1M -697M
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
-
  1. Stock Market
  2. Stocks
  3. A244460 Stock